p53 and bcl-2 in Epithelial Ovarian Carcinoma: Their Value as Prognostic Indicators at a Median Follow-up of 60 Months
- 1 May 2000
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (2), 278-282
- https://doi.org/10.1006/gyno.2000.5780
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian CancerJournal of Clinical Oncology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- p53 Mutations and Expression in Ovarian CancersInternational Journal of Gynecological Pathology, 1999
- Lack of bcl-2 Persistence: An Independent Prognostic Indicator of Poor Prognosis in Endometrial CarcinomaGynecologic Oncology, 1998
- bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up.Journal of Clinical Oncology, 1998
- Quantification of p53 in Epithelial Ovarian CancerGynecologic Oncology, 1997
- bcl-2 Expression, p53 Accumulation, and Apoptosis in Ovarian CarcinomasAmerican Journal of Clinical Pathology, 1996
- Expression and prognostic significance of Bcl-2 in ovarian tumoursBritish Journal of Cancer, 1995
- Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cellsNature, 1988